• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

FDA rejects Biocon and Viatris' Avastin biosimilar after inspection question marks

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 13, 2023 at 10:12: PM
via After the FDA found multiple issues at Biocon’s manufacturing facilities in Malaysia and India, the agency has shot down Biocon and Viatris’ biosimilar to Avastin (bevacizumab).

article source
 




Top Bottom
Back
Quote